<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948476</url>
  </required_header>
  <id_info>
    <org_study_id>6027699</org_study_id>
    <nct_id>NCT04948476</nct_id>
  </id_info>
  <brief_title>Promoting Kidney Recovery After Acute Kidney Injury Receiving Dialysis</brief_title>
  <acronym>Recover-AKI</acronym>
  <official_title>Promoting Kidney Recovery After Acute Kidney Injury Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Silver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to evaluate the feasibility of conducting a randomized&#xD;
      controlled trial comparing a standardized dialysis strategy versus usual care (dialysis&#xD;
      prescription ordered by each patient's primary nephrologist) in patients with AKI-receiving&#xD;
      dialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>2 years</time_frame>
    <description>Recruitment of the target population to the RCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fidelity</measure>
    <time_frame>2 years</time_frame>
    <description>At least 80% of randomized participants remain in the trial and on the allocated study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis-Free Days</measure>
    <time_frame>2 years</time_frame>
    <description>The number of days that a patient did not need dialysis. A patient can only accrue dialysis-free days after the final dialysis session that commences the monitoring period for kidney recovery. Participants who die will be considered to have zero dialysis-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotensive Event on Dialysis</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as a drop in blood pressure requiring one of:&#xD;
Initiation of a vasopressor during renal replacement therapy (RRT) session, OR,&#xD;
Premature discontinuation of RRT session due to blood pressure drop, OR,&#xD;
Any other intervention to stabilize blood pressure during the dialysis session as noted in the nursing record</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Arrhythmia on Dialysis</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as new atrial (excluding sinus tachycardia or sinus arrhythmia) or ventricular arrhythmia that develops during RRT and was not present prior to the initiation of RRT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Standardized Dialysis and Structured Discontinuation (S2D2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prescription to minimize dialysis-induced ischemia and standardize dialysis discontinuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dialysis prescription ordered by their primary nephrologist/intensivist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized Dialysis and Structured Discontinuation (S2D2)</intervention_name>
    <description>Prescription to minimize dialysis-induced ischemia&#xD;
Cool dialysate (35.0◦C)&#xD;
Dialysate sodium of 145mmol/L&#xD;
Dialysate calcium of 1.5mmol/L&#xD;
Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)&#xD;
Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.&#xD;
Structured dialysis discontinuation (all criteria met)&#xD;
Most recent pre-dialysis potassium &lt;6mmo/L and bicarbonate &gt;12mmol/L&#xD;
Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis &lt;1L/session&#xD;
If available, timed urine collection with result for mean creatinine and/or urea clearance &gt;12mL/min</description>
    <arm_group_label>Standardized Dialysis and Structured Discontinuation (S2D2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received ≥2 sessions of any dialysis modality for presumed AKI&#xD;
&#xD;
          -  Plans for continued intermittent hemodialysis or sustained low efficiency dialysis&#xD;
             treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of dialysis for ≥90 days&#xD;
&#xD;
          2. Known baseline estimated glomerular filtration rate (eGFR) &lt;15mL/min/1.73m2&#xD;
&#xD;
          3. Strong clinical suspicion of urinary tract obstruction, rapidly progressive&#xD;
             glomerulonephritis (RPGN), vasculitis, thrombotic microangiopathy (TMA), myeloma&#xD;
             related cast nephropathy, or acute interstitial nephritis (AIN) as the underlying&#xD;
             cause of AKI&#xD;
&#xD;
          4. Receipt of any dialysis prior to the current admission within the past 2 months&#xD;
&#xD;
          5. Kidney transplant within the past 12 months&#xD;
&#xD;
          6. Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel A Silver</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel A Silver</last_name>
    <phone>613-549-6666</phone>
    <email>samuel.silver@queensu.ca</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Samuel Silver</investigator_full_name>
    <investigator_title>Dr. Samuel A Silver</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified patient data will be available up to 3 years after manuscript publication to researchers with methodologically sound proposals approved by the principal investigator.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Up to 3 years after manuscript publication</ipd_time_frame>
    <ipd_access_criteria>Available to researchers with methodologically sound proposals approved by the principal investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

